相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
ABCB1 andABCG2Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib
Wenlong Li et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
Mi Ran Yun et al.
CLINICAL CANCER RESEARCH (2020)
Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry
Wenlong Li et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
CNS metastasis in ROS1 + NSCLC: An urgent call to action, to understand, and to overcome
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2019)
444PDSafety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
A Drilon et al.
ANNALS OF ONCOLOGY (2019)
Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib
Wenlong Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
Diana Cervantes-Madrid et al.
SCIENTIFIC REPORTS (2019)
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib
Wenlong Li et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
Wenlong Li et al.
PHARMACOLOGICAL RESEARCH (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
What do drug transporters really do?
Sanjay K. Nigam
NATURE REVIEWS DRUG DISCOVERY (2015)
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Seng Chuan Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Tumor-Specic Expression of Organic Anion-Transporting Polypeptides: Transporters as Novel Targets for Cancer Therapy
Veronika Buxhofer-Ausch et al.
JOURNAL OF DRUG DELIVERY (2013)
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
Sai-Hong Ignatius Ou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
Enrique Grande et al.
MOLECULAR CANCER THERAPEUTICS (2011)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs
Evita van de Steeg et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
Hiroshi Kodaira et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Blood-brain barrier transporters and response to CNS-active drugs
Bradley L. Urquhart et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Cytochrome P450-mediated metabolism in the human gut wall
Kirstin Thelen et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2009)
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
Antonius E. van Herwaarden et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Predicting drug sensitivity and resistance:: Profiling ABC transporter genes in cancer cells
G Szakács et al.
CANCER CELL (2004)
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
AH Schinkel et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
JW Jonker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
